Cargando…
Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate
BACKGROUND: Recombinant human interleukin-2 (rhIL-2, aldesleukin) is Food and Drug Administration approved for the treatment of metastatic melanoma and renal cell carcinoma and has achieved durable response in a subset of patients. However, its utility as an immunotherapeutic drug is limited by unde...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772458/ https://www.ncbi.nlm.nih.gov/pubmed/35058325 http://dx.doi.org/10.1136/jitc-2021-003155 |